Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Much Delay In Alzheimer’s Disease Progression Is Clinically Meaningful?

Executive Summary

US FDA agrees with Eisai/Biogen that half a point change in cognitive scale, which sponsor says means a five month delay in decline, is a clinically meaningful benefit. But others contend the treatment effect is small and does not outweigh risk of brain bleeds.

You may also be interested in...

Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?

More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.

US FDA Sees Leqembi Data As Vindicating Its Approach To Alzheimer’s Drugs

Two-and-a-half years after Aduhelm’s tumultuous advisory committee, FDA finally gets positive vote it was looking for, albeit on a different product. Leqembi meeting serves to endorse CDR-SB as clinical endpoint as well as amyloid plaque as surrogate for reduction in decline.

Eisai/Biogen’s Leqembi Breezes Through Adcomm, Labeling Discussions With US FDA May Be Knottier

To get traditional approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts